A new study introduces XL20, an experimental small-molecule drug that crosses the blood-brain barrier to selectively block a toxic region on the TDP-43 protein. This precise mechanism halts neuron death and slows muscle wasting in ALS models while leaving the protein's healthy, vital biological functions completely intact.
